Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial

  • Kim, Min Chul; 
  • Ahn, Joon Ho; 
  • Hyun, Dae Young; 
  • Lim, Yongwhan; 
  • Lee, Seung Hun; 
  • 외 21명
Citations

WEB OF SCIENCE

7
Citations

SCOPUS

7

초록

Background Current guidelines recommend complete revascularization (CR) in hemodynamically stable patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD). With regard to the timing of percutaneous coronary intervention (PCI) for non-infarct-related artery (non-IRA), recent randomized clinical trials have revealed that immediate CR was non-inferior to staged CR. However, the optimal timing of CR remains uncertain. The OPTION-STEMI trial compared immediate CR and in-hospital staged CR guided by fractional flow reserve (FFR) for intermediate stenosis of the non-IRA. Methods The OPTION-STEMI is a multicenter, investigator-initiated, prospective, open-label, non-inferiority randomized clinical trial. The study included patients with at least 1 non-IRA lesion with >= 50% stenosis by visual estimation. Patients fulfilling the inclusion criteria were randomized into 2 groups at a 1:1 ratio: immediate CR (i.e., PCI for the non-IRA performed during primary angioplasty) or in-hospital staged CR. In the in-hospital staged CR group, PCI for non-IRA lesions was performed on another day during the index hospitalization. Non-IRA lesions with 50%-69% stenosis by visual estimation were evaluated by FFR, whereas those with >= 70% stenosis was revascularized without FFR. The primary endpoint was the composite of all-cause death, non-fatal myocardial infarction, and all unplanned revascularization at 1 year after randomization. Enrolment began in December 2019 and was completed in January 2024. The follow-up for the primary endpoint will be completed in January 2025, and primary results will be available in the middle of 2025. Conclusions The OPTION-STEMI is a multicenter, non-inferiority, randomized trial that evaluated the timing of in-hospital CR with the aid of FFR in patients with STEMI and MVD.

키워드

PERCUTANEOUS CORONARY INTERVENTION; LESION-ONLY REVASCULARIZATION; ARTERY REVASCULARIZATION; RANDOMIZED-TRIAL; FOLLOW-UP; ANGIOPLASTY; GUIDELINES; PCI
제목
Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial
저자
Kim, Min Chul; Ahn, Joon Ho; Hyun, Dae Young; Lim, Yongwhan; Lee, Seung Hun; Oh, Seok; Hoon, Kyung; Sim, Doo Sun; Hong, Young Joon; Kim, Ju Han; Jeong, Myung Ho; Cho, Jang Hyun; Lee, Sang-Rok; Kang, Dong Oh; Hwang, Jin-Yong; Youn, Young Jin; Jeong, Young-Hoon; Park, Yongwhi; Kim, Dong-Bin; Choo, Eun-Ho; Kim, Chan Joon; Kim, Weon; Rhew, Jay Young; Lee, Jung-Hee; Yoo, Sang-Yong; Ahn, Andyoungkeun
DOI
10.1016/j.ahj.2024.03.017
발행일
2024-07
유형
Article
저널명
American Heart Journal
권
273
페이지
35 ~ 43